Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 in Advanced Solid Tumors
NCT05781048Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-6209 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Adverse Events at 2 years, Dose-Limiting Toxicity at 30 days and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
HRS-6209
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05781048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781048.